Inhibiting TGF-β activity improves respiratory function in mdx mice.
about
SIRT1: A Novel Target for the Treatment of Muscular DystrophiesPre-clinical drug tests in the mdx mouse as a model of dystrophinopathies: an overviewThe role of fibrosis in Duchenne muscular dystrophyOverexpression of Latent TGFβ Binding Protein 4 in Muscle Ameliorates Muscular Dystrophy through Myostatin and TGFβModifier genes and their effect on Duchenne muscular dystrophyPhospholipase A2 in experimental allergic bronchitis: a lesson from mouse and rat modelsBiochemical and Functional Comparisons of mdx and Sgcg(-/-) Muscular Dystrophy Mouse Models.Targeting TGF-β Signaling by Antisense Oligonucleotide-mediated Knockdown of TGF-β Type I Receptor.Improving Reproducibility of Phenotypic Assessments in the DyW Mouse Model of Laminin-α2 Related Congenital Muscular Dystrophy.LTBP4 genotype predicts age of ambulatory loss in Duchenne muscular dystrophy.Pharmacologic management of Duchenne muscular dystrophy: target identification and preclinical trialsInflammatory monocytes promote progression of Duchenne muscular dystrophy and can be therapeutically targeted via CCR2.Early right ventricular fibrosis and reduction in biventricular cardiac reserve in the dystrophin-deficient mdx heart.A Wnt-TGFβ2 axis induces a fibrogenic program in muscle stem cells from dystrophic mice.Dimorphic effects of transforming growth factor-β signaling during aortic aneurysm progression in mice suggest a combinatorial therapy for Marfan syndromeLife or death by NFκB, Losartan promotes survival in dy2J/dy2J mouse of MDC1A.Chronic Dosing with Membrane Sealant Poloxamer 188 NF Improves Respiratory Dysfunction in Dystrophic Mdx and Mdx/Utrophin-/- MiceGenotype-Specific Interaction of Latent TGFβ Binding Protein 4 with TGFβ.Hypoxia-induced cardiac injury in dystrophic mice.Modifying muscular dystrophy through transforming growth factor-β.Conditional expression of TGF-β1 in skeletal muscles causes endomysial fibrosis and myofibers atrophyCoronary adventitial cells are linked to perivascular cardiac fibrosis via TGFβ1 signaling in the mdx mouse model of Duchenne muscular dystrophy.Prospect for pharmacological therapies to treat skeletal muscle dysfunction.Drug Discovery of Therapies for Duchenne Muscular Dystrophy.A healthy tension in translational research.Fibrillin-1 Regulates Skeletal Stem Cell Differentiation by Modulating TGFβ Activity Within the Marrow Niche.Muscle cell communication in development and repair.Andrographolide attenuates skeletal muscle dystrophy in mdx mice and increases efficiency of cell therapy by reducing fibrosis.Motor performance of young dystrophic mdx mice treated with long-circulating prednisolone liposomes.Excess SMAD signaling contributes to heart and muscle dysfunction in muscular dystrophy.Targeting latent TGFβ release in muscular dystrophy.ECM-Related Myopathies and Muscular Dystrophies: Pros and Cons of Protein Therapies.Biochemical and morphological alterations in the Achilles tendon of mdx mice.Therapeutic effects of mouse adipose-derived stem cells and losartan in the skeletal muscle of injured mdx mice.Non-Glycanated Biglycan and LTBP4: Leveraging the extracellular matrix for Duchenne Muscular Dystrophy therapeutics.The dual CCR2/CCR5 chemokine receptor antagonist Cenicriviroc reduces macrophage infiltration and disease severity in Duchenne muscular dystrophy (Dmdmdx-4Cv) mice.
P2860
Q26748736-4B55C88E-54D7-44D3-94CE-418E65AB0764Q26849430-39141B29-44F6-45E1-8B99-FA6C86E3442DQ27024049-0AC75B4D-635D-4C06-AC41-5CC75FC2402EQ27308903-64C2C5FE-2D3E-4690-A417-82D3499AABE0Q28083441-944D52E1-F8F1-4A20-B1DE-C2BB7058EE30Q28534706-B9FFCDAA-8AFC-445A-AA2A-34A67FFAB398Q30650746-2567F9E8-3B1D-473B-A8E7-9C212C095F2CQ33570741-C34CAE98-8D24-42F1-8AC6-9CFB2331556BQ33787898-F66C2010-66C8-4EAA-9426-D323563C588DQ33931637-D3802B89-94E4-4749-B6CD-19DD9B0C2F08Q34152280-35844B74-BC2A-4189-9B1A-0A541BC88531Q34542698-F3B095D1-0BDC-4C93-BE0F-38541324E66BQ35086442-B10C3206-DF24-4AFF-A596-AD8407848F32Q35150743-DF750DF8-6264-4885-A0D3-E33DF7CB7A5EQ35224497-84BDEE65-1C71-4AD2-AD27-67AB89332E40Q35274694-1CA072C4-265B-4B08-9A2C-FFB32F054124Q35738899-BDDDBA36-25F5-469F-A606-C1E73DA265D6Q35937127-2EC796B6-98A7-44BB-9AEF-B1C3D3612F05Q36895785-3CA03AE9-1DE0-45A9-87A4-2CB6F9E4C265Q37064241-4E528701-FF0B-4DBE-B4C6-5B23AB010E21Q37309267-A72C0CC6-93B6-4501-B5BA-E40F5DFA45E7Q37325205-59C0FF22-70BF-4AD7-B895-CF5ADF662058Q38264369-83D115CD-9F10-4C8E-AD7F-B245BF4A0306Q38480698-B8FAAD6B-8DA0-428F-89B8-27129155CD70Q38592372-66725702-0A99-41AB-8374-258B5958201BQ38851482-0518688B-85CB-43F5-A506-4993834F7EDBQ39248771-92B22EF8-B41C-4913-877D-00AFA2DD3898Q39629598-FBF23FE5-7123-45AF-868B-8C8C87A3939EQ39663447-51B0F728-747F-4355-9B4F-4FA2833F44B1Q41902894-BBEF69B6-81D5-4CAF-8227-02E7FED30D53Q41965451-6FFA8B8A-B0B9-48CE-B187-87771A7D25BFQ45871995-19D4AD61-E7CC-4A63-8E5A-62CB44377058Q50221125-E3238BD8-FAD1-4426-8282-07611751C4C0Q50460163-FEE0D482-0582-409A-9649-A473B9BD5862Q52372774-B0AC1617-DEE3-4137-9668-790292D6957DQ52644936-9D9038B9-22A1-4A00-B665-94AC0EAAA244
P2860
Inhibiting TGF-β activity improves respiratory function in mdx mice.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Inhibiting TGF-β activity improves respiratory function in mdx mice.
@en
Inhibiting TGF-β activity improves respiratory function in mdx mice.
@nl
type
label
Inhibiting TGF-β activity improves respiratory function in mdx mice.
@en
Inhibiting TGF-β activity improves respiratory function in mdx mice.
@nl
prefLabel
Inhibiting TGF-β activity improves respiratory function in mdx mice.
@en
Inhibiting TGF-β activity improves respiratory function in mdx mice.
@nl
P2093
P2860
P1476
Inhibiting TGF-β activity improves respiratory function in mdx mice.
@en
P2093
Alison McVie-Wylie
Bruce M Wentworth
Carol A Nelson
Carol J Dinardo
Jennifer A McCullough
John P Leonard
Kelly A Keefe
Lindsay A Quigley
Lorena Ceci
Nicholas P Clayton
P2860
P304
P356
10.1016/J.AJPATH.2011.02.024
P407
P577
2011-06-01T00:00:00Z